All In Biotech

Drug Trial Radar · NCT05424887

A Study to Evaluate the Efficacy and Safety of AK3280 in Patients With Idiopathic Pulmonary Fibrosis

A Randomized, Double-blind, Multi-center Phase II Clinical Study to Evaluate the Efficacy and Safety of Two Different Dose Groups of AK3280 in Patients With Idiopathic Pulmonary Fibrosis (IPF) Compared to the Placebo Control Group

Last checked: Nov 19, 2026Latest source record: Jul 20, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 105 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

105

Planned (sponsor's estimate)

Start

Jul 2022

Primary completion

Jul 2024

Study completion Oct 2024

Sponsor

Sponsor type
Industry
First posted
Jun 21, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 40 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized, double-blind, placebo-controlled, multi-center phase II clinical study conducted in China to compare the efficacy and safety of two different dose groups of AK3280 in IPF patients compared to the placebo control group.

Conditions

  • Idiopathic Pulmonary Fibrosis

Interventions

  • AK3280Drug

    Active Substance: AK3280, Pharmaceutical Form: Tablet, Route of Administration: Oral

  • PlaceboDrug

    Active Substance: Placebo, Pharmaceutical Form: Tablet, Route of Administration: Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. After 24 weeks of continuous medication, the absolute decrease in percentage of the predicted FVC from baseline in the AK3280 treatment group compared to the placebo control group.Time frame: Up to 24 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • China-Japan Friendship Hospital

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.